Compass Therapeutics (CMPX) Reiterated at Market Outperform by Citizens on PFS, OS Results
Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $10.00 price target on Compass Therapeutics (NASDAQ: CMPX).The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)